# Surufatinib in Combination With Iparomlimab and Tuvonralimab Injection and AG Chemotherapy for Neoadjuvant Therapy of HRPC or BRPC

Source: https://onco.cc/trials/nct07833241/  
OnCo record `nct07833241` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of gemcitabine + nab-paclitaxel, gemcitabine, capecitabine and fOLFIRINOX / mFOLFIRINOX in pancreatic cancer, run by Shanghai Zhongshan Hospital, not yet recruiting.

## Summary

Surufatinib in Combination With Iparomlimab and Tuvonralimab Injection and AG Chemotherapy for Neoadjuvant Therapy of HRPC or BRPC is a phase 2, interventional study registered as NCT07833241 by Shanghai Zhongshan Hospital, with a registry enrolment figure of 56 participants, started 2026-09-01 and due to reach its primary completion in 2028-09-01. Interventions recorded: Surufatinib Plus Iparomlimab and Tuvonralimab and AG Chemotherapy; Gemcitabine plus Capecitabine; Modified FOLFIRINOX. Conditions listed: Borderline Resectable Pancreatic Cancer; High-Risk Resectable Pancreatic Cancer. Primary outcome: 12-month Event Free Survival (EFS) rate. Pancreatic eligibility wording from the registry: "* Patients with high-risk resectable or borderline resectable pancreatic adenocarcinoma confirmed by histopathology or cytology". Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-24
- Also known as: ZSPAC-22
- Tags: ctgov-ingest; pancreatic-deep-dive
- Registry id: NCT07833241
- Phase: 2
- Setting: Neoadjuvant Surufatinib in Combination With Iparomlimab and Tuvonralimab Injection and AG Chemotherapy for High-risk Resectable or Borderline Resectable Pancreatic Cancer: a Single-arm, Single-center, Exploratory Clinical Study
- Sponsor: Shanghai Zhongshan Hospital
- Enrolled: 56

## Sources

- ClinicalTrials.gov NCT07833241: https://clinicaltrials.gov/study/NCT07833241

## Connected records

- cancers: [Borderline resectable pancreatic ductal adenocarcinoma](https://onco.cc/cancers/borderline-resectable-pdac/), [Resectable pancreatic ductal adenocarcinoma](https://onco.cc/cancers/resectable-pdac/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/), [Platinum agents](https://onco.cc/technologies/platinum/), [Topoisomerase-I inhibitors (and ADC payloads)](https://onco.cc/technologies/topoisomerase-inhibitors/)
- drugs: [Capecitabine](https://onco.cc/drugs/capecitabine/), [FOLFIRINOX / mFOLFIRINOX](https://onco.cc/drugs/folfirinox/), [Gemcitabine](https://onco.cc/drugs/gemcitabine/), [Gemcitabine + nab-paclitaxel](https://onco.cc/drugs/gemcitabine-nab-paclitaxel/)
- terms: [Pancreatic cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/pancreatic-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07833241.json